Osicent 80 mg is a targeted therapy containing osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by IEB Pharma. It is specifically designed for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, including exon 19 deletions, exon 21 L858R mutations, and the T790M resistance mutation. Osimertinib works by irreversibly binding to these mutant forms of EGFR, thereby inhibiting tumor growth and progression. The recommended dosage is 80 mg orally once daily, with or without food, continuing until disease progression or unacceptable toxicity occurs. Common side effects associated with Osicent include diarrhea, rash, dry skin, and nail toxicity. Patients are advised to consult with their healthcare provider to determine if Osicent is the appropriate treatment option for their specific condition.Osicent 80 mg is a targeted therapy containing osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Incepta Pharmaceuticals Ltd. It is specifically designed for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, including exon 19 deletions, exon 21 L858R mutations, and the T790M resistance mutation. Osimertinib works by irreversibly binding to these mutant forms of EGFR, thereby inhibiting tumor growth and progression. The recommended dosage is 80 mg orally once daily, with or without food, continuing until disease progression or unacceptable toxicity occurs. Common side effects associated with Osicent include diarrhea, rash, dry skin, and nail toxicity. Patients are advised to consult with their healthcare provider to determine if Osicent is the appropriate treatment option for their specific condition.